Haemonetics Statistics
Share Statistics
Haemonetics has 48.04M
shares outstanding. The number of shares has increased by -1.4%
in one year.
| Shares Outstanding | 48.04M |
| Shares Change (YoY) | -1.4% |
| Shares Change (QoQ) | 0.03% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 3 |
| FTD / Avg. Volume | n/a |
Short Selling Information
The latest short interest is 4.08M, so 8.48% of the outstanding
shares have been sold short.
| Short Interest | 4.08M |
| Short % of Shares Out | 8.48% |
| Short % of Float | 13.78% |
| Short Ratio (days to cover) | 5.94 |
Valuation Ratios
The PE ratio is 18.97 and the forward
PE ratio is 13.95.
Haemonetics's PEG ratio is
0.44.
| PE Ratio | 18.97 |
| Forward PE | 13.95 |
| PS Ratio | 2.34 |
| Forward PS | 2.1 |
| PB Ratio | 3.87 |
| P/FCF Ratio | 22.33 |
| PEG Ratio | 0.44 |
Financial Ratio HistoryEnterprise Valuation
Haemonetics has an Enterprise Value (EV) of 3.18B.
| EV / Sales | 2.33 |
| EV / EBITDA | 14.32 |
| EV / EBIT | 17.48 |
| EV / FCF | 22.3 |
Financial Position
The company has a current ratio of 1.62,
with a Debt / Equity ratio of 0.37.
| Current Ratio | 1.62 |
| Quick Ratio | 0.99 |
| Debt / Equity | 0.37 |
| Debt / EBITDA | 1.37 |
| Debt / FCF | 2.13 |
| Interest Coverage | -22.76 |
Financial Efficiency
Return on Equity is 20.43% and Return on Invested Capital is 8.06%.
| Return on Equity | 20.43% |
| Return on Assets | 6.84% |
| Return on Invested Capital | 8.06% |
| Revenue Per Employee | $372,114.85 |
| Profits Per Employee | $45,851.52 |
| Employee Count | 3,657 |
| Asset Turnover | 0.56 |
| Inventory Turnover | 1.68 |
Taxes
| Income Tax | 44.39M |
| Effective Tax Rate | 20.93% |
Stock Price Statistics
The stock price has increased by -19.74% in the
last 52 weeks. The beta is 0.32, so Haemonetics's
price volatility has been higher than the market average.
| Beta | 0.32 |
| 52-Week Price Change | -19.74% |
| 50-Day Moving Average | 63.72 |
| 200-Day Moving Average | 72.33 |
| Relative Strength Index (RSI) | 56.59 |
| Average Volume (20 Days) | 687,973 |
Income Statement
In the last 12 months, Haemonetics had revenue of 1.36B
and earned 167.68M
in profits. Earnings per share was 3.31.
| Revenue | 1.36B |
| Gross Profit | 748.96M |
| Operating Income | 221.82M |
| Net Income | 167.68M |
| EBITDA | 221.82M |
| EBIT | n/a |
| Earnings Per Share (EPS) | 3.31 |
Full Income StatementBalance Sheet
The company has 306.76M in cash and 303.56M in
debt, giving a net cash position of 3.21M.
| Cash & Cash Equivalents | 306.76M |
| Total Debt | 303.56M |
| Net Cash | 3.21M |
| Retained Earnings | 352.17M |
| Total Assets | 2.45B |
| Working Capital | 356.86M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was 181.72M
and capital expenditures -39.28M, giving a free cash flow of 142.45M.
| Operating Cash Flow | 181.72M |
| Capital Expenditures | -39.28M |
| Free Cash Flow | 142.45M |
| FCF Per Share | 2.83 |
Full Cash Flow StatementMargins
Gross margin is 55.04%, with operating and profit margins of 16.3% and 12.32%.
| Gross Margin | 55.04% |
| Operating Margin | 16.3% |
| Pretax Margin | 15.58% |
| Profit Margin | 12.32% |
| EBITDA Margin | 16.3% |
| EBIT Margin | 16.3% |
| FCF Margin | 10.47% |
